3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
8
Recruiting
6
Active not recruiting
5
Withdrawn
4
Terminated
3
Unknown
1
Available
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
21
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Neoplasm, Residual
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Burkitt Lymphoma
1
Interventions
Dexamethasone
64
Cyclophosphamide
40
Bortezomib
37
Melphalan
24
Lenalidomide
23
Thalidomide
17
pomalidomide
16
fludarabine
12
daratumumab
11
carfilzomib
10
Filgrastim
8
Doxorubicin
8
Busulfan
6
Prednisone
5
Peripheral Blood Stem Cell Transplantation
5
Bendamustine Hydrochloride
5
selinexor
4
sargramostim
4
isatuximab
4
fludarabine phosphate
4
Surveys and Questionnaires
4
Etoposide
4
Clarithromycin
4
Calcium Dobesilate
4
liposomal doxorubicin
3
ixazomib
3
Radiotherapy
3
Neoadjuvant Therapy
3
Mycophenolic Acid
3
Methylprednisolone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Multiple Myeloma
×
venetoclax
×
Clear all
NCT05005299
2023-08-01
VICTORY
Melbourne Health
Phase 1
Unknown
18 enrolled